bioRxiv ScienceSearch

Biology subjects

Schuler, J.

Publications and source records attributed to Schuler, J..

2 recordsLinked to original sources

Fingerprinting CANDO: Increased Accuracy with Structure and Ligand Based Shotgun Drug Repurposing

We have upgraded our Computational Analysis of Novel Drug Opportunities (CANDO) platform for shotgun drug repurposing to include ligand-based, data fusion, and decision tree pipelines. The first version of CANDO implemented a structure-based pipeline that modeled interactions between compounds and proteins on a large scale, generating compoundproteome interaction signatures used to infer similarity of drug behavior; the new pipelines accomplish this by incorporating molecular fingerprints and the Tanimoto coefficient. We obtain improved benchmarking performance with the new pipelines across all three evaluation metrics used: average indication accuracy, pairwise accuracy, and coverage. The best performing pipeline achieves an average indication accuracy of 19.0% at the top10 cutoff, compared to 11.7% for v1, and 2.2% for a random control. Our results demonstrate that the CANDO drug recovery accuracy is substantially improved by integrating multiple pipelines, thereby enhancing our ability to generate putative therapeutic repurposing candidates, and increasing drug discovery efficiency.

bioinformatics

Exploration of interaction scoring criteria in the CANDO platform

BackgroundDrug discovery is an arduous process that requires many years and billions of dollars before approval for patient use. However, there are a number of drugs and human ingestibles approved for a variety of indications/diseases that can be potentially repurposed as new treatments for others, decreasing the time and cost required.\n\nMethodsCANDO (Computational Analysis of Novel Drug Opportunities) is a platform for shotgun, multitarget drug discovery and repurposing. The CANDO platform scores interactions between 46,784 proteins structures and 3,733 human use compounds using a bioinformatic docking protocol to generate compound-proteome interaction signatures that are then compared to identify candidates for repurposing. Benchmarking of the platform is accomplished by comparing the compound-proteome interaction signatures and determining whether signatures corresponding to pairs of drugs approved for the same indication fall within particular cutoffs.\n\nResultsWe have altered the scoring function of bioinformatic docking protocol in the newest version of our platform (v1.5) to use the best OBscore for each compound-protein interaction, resulting in an increased benchmarking accuracy from 11.7% in v1 to 12.8% in v1.5 for the top10 cutoff, the most stringent one used, and correspondingly from 24.9% to 31.2% for the top100 cutoff.\n\nConclusionsThe change in the interaction scoring and other bug fixes in CANDO v1.5 have resulted in improved benchmarking performance, making the platform more effective at predicting novel, therapeutic drug-indication pairs.

bioinformatics